Global contract research organization (CRO) providing specialty laboratory services to support the entire drug development cycle.
USA, CAN, BE, AUS, CHN
Joined November 2011
- Tweets1.4K
- Following1.1K
- Followers1K
- Likes718
Our flow cytometry and proteomics expertise was on show this week with posters at AAPS PHarmSci360 and the Australasian Cytometry Society.
2️⃣ Assessing Inter-instrument Flow Cytometer Alignment ➡️
buff.ly/WTx6sh0
3️⃣Highly Sensitive B-Cell Monitoring Following B-Cell-Depleting Therapies
➡️ buff.ly/EdkuKNP
The CellCarta Team is heading to SITC! This is a great opportunity to grab one-on-one time with the team and discover how our scientific experts develop and deploy assays to collect the critical information your program needs.
Book a meeting here: buff.ly/PzN9xZH
Every October, Breast Cancer Awareness Month reminds us why our work is critically important.
To the patients, caregivers, clinicians, and researchers committed to advancing therapeutics in breast cancer: thank you for the work you do.
We are proud to support it.
Let's Talk! In our latest webcast, we discuss the realities of building and commercializing CAR-T therapies with Dr. John Rossi, a leader in the field of CAR-T therapy.
Watch the full conversation here: buff.ly/BTfbYHf
📌 Global Expertise + Local Presence
We're thrilled to be at AusBiotech this week - visit Pierre Gontard and Kevin Lo at Booth 118 in Gold Coast!
Drop by to discuss how we can support your local programs and global trials with our site in Sydney, global labs and expertise.
Gold Coast! We're excited to be heading to AusBiotech - come say hi at Booth 118, from October 21 to 23.
Bring your biomarker questions - from multi-modal global trials to keeping your immunology testing local, our experts are excited to discuss how we can support your programs.
Announcement! CellCarta and Tivenix are expanding their partnership.
Tivenix's AI-powered platform applies bioinformatics to the epigenetic analysis of cell-free DNA and other tissue-derived signals, supporting precision medicine applications.
Read here: buff.ly/L8RIN9p
Did we miss you in Basel? We're still available to chat! 👋
We're always excited to discuss the biggest challenges facing your programs, from translational research to CDx commercialization. If we missed you in Basel, send us a message to connect ✉️ buff.ly/0gMp5PK
CellCarta's Christopher Ung is the Conference Chair for this afternoon's World CB and CDx Summit sessions.
Join him for two engaging sessions covering diverse topics across clinical biomarkers and CDx development.
See you there!
We're pleased to announce a strategic partnership with Waters Corporation to advance companion diagnostics (CDx) development. buff.ly/CRDVBPf
The collaboration creates a framework to jointly pursue CDx and next-generation flow cytometry opportunities with biopharma.
including through our laboratory in China.
"By combining CellCarta's end-to-end laboratory capabilities with Waters' diagnostic and CDx development expertise, and flow cytometry platforms, we can help sponsors reduce complexity, preserve program continuity
and make earlier, more informed decisions about how to scale their programs." Todd Chermak, President, CellCarta
Read the full release: buff.ly/CRDVBPf
We're bringing the CellCarta team to Basel for an afternoon built around your biomarker challenges.
Spaces are limited, so reserve yours here: buff.ly/eUmM6Kl
📅Oct 7, 12:10 PM
Presentation: The CDx Model Needs to Change. What China taught us about breaking silos, moving faster and going global
📅Oct 8, 11:20 AM,
Presentation: Can AI Predict ADC Response? With Siraj A. of Lunit, on discovering, validating and deploying AI biomarkers faster
If you'd rather talk through your own program, the CellCarta team will be in Boston all week. Book here: buff.ly/g38Az8B